guidelines on non-cardiac surgery 2014 (tf32) - tf members

Anker Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BG medicine : Biomarker in heart failure (2012)

- Applied Clinical Intelligence, LLC : Endpoint adjudication COPD (2012)

- Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2012)

- Amgen Inc : SAB heart failure (2012)

- Novartis : Cachexia therapy (2012-2013)

- GlaxoSmithKline : Cachexia therapy (2012-2013)

- St Jude Medical : Telemonitoring (2012-2013)

- Bosch AG Germany : Telemonitoring (2012-2013)

- BRAHMS GmbH : Biomarker in heart failure (2012-2013-2014)

- GTx : Cachexia therapy (2012-2013-2014)

- PsiOxus Therapeutics : Cachexia therapy in cancer (2012-2013-2014)

- Abbott Vascular : Device heart failure (2012-2013-2014)

- Impulse Dynamics : Device in heart failure (2012-2013-2014)

- Lone Star Heart : Device in heart failure (2012-2013-2014)

- Pluristem Therapeutics : DSMB - stem cells for muscle wasting (2012-2013-2014)

- Servier : Heart failure (2012-2013-2014)

- Menarini : Heart failure (2012-2013-2014)

- Cardiomems : Heart failure (2012-2013-2014)

- Bayer AG : Heart failure (2012-2013-2014)

- Medical Sensible : Heart failure (2012-2013-2014)

- Vifor International : iv Iron therapy for heart failure (2012-2013-2014)

- Relypsa : K+ Resin (2012-2013-2014)

29/07/2014

Guidelines on Non-Cardiac Surgery 2014 (TF32) - TF MEMBERS

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

of 45

Anker Stefan - Novartis : SAB heart failure (2012-2013-2014)

- Cardiorentis : TRUE-AHF trial, executive committee (2012-2013-2014)

- Metabolic Research srl (Italy) : Nutrition for Muscle Wasting / Cachexia (2013-2014)

- Cardiokinetix : SAB heart failure (2013-2014)

- Bioventrix : SAB in heart failure (2013-2014)

- Respicardia : SAB phrenic nerve stimulation (2013-2014)

- Astra Zeneca : HF lecture (2014)

- PharmaGenesis : Medical Writing Support (2014)

- Medtronic : SAB (2014)

- BG medicine : SAB for biomarker guided therapy (2014)

D - Research funding (departmental or institutional). - Impulse Dynamics : Heart failure (2012)

- Medical Sensible : Heart failure (2012)

- Novartis : cachexia research (2012-2013)

- Metabolic Research srl (Italy) : Cachexia nutrition research (2012-2013-2014)

- PsiOxus Therapeutics : Cancer cachexia (2012-2013-2014)

- Vifor International : CHF therapy development (2012-2013-2014)

- Bayer AG : CHF therapy development (2012-2013-2014)

- Abbott Vascular : Heart failure (2012-2013-2014)

- Aveo Oncology : Cachexia Research (2013-2014)

Botker Hans Erik None declared (2012-2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Antithromotic therapy (2014)

29/07/2014




of 45

De Hert Stefan None declared (2012-2013-2014)

Ford Ian B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire Pharmaceuticals : angioedema (2012)

- The Medicines Company : bivalirudin (2012)

- Actamax : Adhesion Prevention (2012-2013-2014)

- GlaxoSmithKline : Ambrisentan (2012-2013-2014)

- Pfizer : Celecoxib (2012-2013-2014)

- Biotronik : CRT-D (2012-2013-2014)

- CRI GmbH : DSMB membership (2012-2013-2014)

- Phagenesis : Dysphagia (2012-2013-2014)

- Shire Pharmaceuticals : enzyme replacement therapy (2012-2013-2014)

- Novartis : Everilimus (2012-2013-2014)

- Menarini : Gout (2012-2013-2014)

- Medtronic : Insulin pump (2012-2013-2014)

- Servier : Ivabradine (2012-2013-2014)

- NovoNordisk : Liraglutide (2012-2013-2014)

- Astra Zeneca : MEDI2070 (2012-2013-2014)

- MedImmune : MEDI8968 (2012-2013-2014)

- Novartis : Pasireotide (2012-2013-2014)

- GlaxoSmithKline : Prolyl Hydroxylase Inhibitor (2012-2013-2014)

- Servier : Trimetazadine (2012-2013-2014)

- Guidant : Vagal nerve stimulation (2012-2013-2014)

- The Medicines Company : Everilimus (2013-2014)

29/07/2014




of 45

Ford Ian D - Research funding (departmental or institutional). - Menari ni : Cardiovascular (2012)

- GlaxoSmithKline : data monitoring committees support, muscular dystropy, pulmonary hypertension, anaemia,ophthalmology (2012)

- Vifor Pharma : iron supplementation (2012)

- Medvance : abdominal aortic aneurysm (2012-2013-2014)

- Rainer Technology Ltd : artifical disc replacement (2012-2013-2014)

- Pfizer : Celecoxib (2012-2013-2014)

- Biotronik : CRT-D (2012-2013-2014)

- Medtronic : diabetes (2012-2013-2014)

- Menarini : Gout (2012-2013-2014)

- Alexion : Guillain Barré (2012-2013-2014)

- Vifor Pharma ltd : Heart failure (2012-2013-2014)

- Medvance : Infection (2012-2013-2014)

- Hoffman La Roche : Inflammatory and Immune (2012-2013-2014)

- Pfizer : Inflammatory and Immune System (2012-2013-2014)


- GlaxoSmithKline : metabolic and endocrine (2012-2013-2014)

- ClinTec : metabolic and endocrine (2012-2013-2014)

- Bio-Medical Research Ltd : Muskuloskeletal, Renal, Urogenital (2012-2013-2014)

- Codman Neurological : Neurology (2012-2013-2014)

- Patients Direct : Pain (2012-2013-2014)

- Reneuron : Stem cell therapy (2012-2013-2014)

29/07/2014




of 45

Ford Ian - Microtransponder : Stroke (2012-2013-2014)

- GlaxoSmithKline : anaemia,pulmonary hypertension,ophthalmology,wound healing (2013-2014)

- Menarini : Cardiovascular (2013-2014)

- Vifor Pharma : iron supplementation in dialysis (2013-2014)

Funck-Brentano Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis CH : Adjudication Committee on an immunosuppressant (2012)

- Shire HGT : Cardiac safety of an antidiarrheal drug (2012)

- Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2012)

- Actelion : Consulting on the potential udevelopement of a calcium inhibitor (2012)

- Bristol Myers Squibb : Discussion on an educational program for stroke prevention in AF (2012)

- CEPHALON : DSMB in an oncology phase IIb trial (2012)

- Lundbeck : Cardiac safety of an antidepressant (2012-2013)

- MMV (CH) : Cardiac Saftey of two antimalarial drugs (2012-2013)

- Pierre-Fabre : Cardiac Safety of non-cardiovasclar products (2012-2013-2014)

- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2012-2013-2014)

- Actelion : Consulting on the potential developement of a calcium inhibitor (2013)

- Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2013-2014)

- Teva Pharmaceutical Industries : DSMB in an oncology phase IIb trial (2013-2014)

- Ipsen : Cardiac safety of a product used for bowel preparation (2014)

- Intracellular Therapies USA : Cardiac safety of a psychotropic drug (2014)

- MMV (CH) : Cardiac Saftey of two antimalarial drugs - DSMB member (2014)

29/07/2014




of 45

Funck-Brentano Christian - Banook CRO : Chairmanship of a DSMB on a SANOFI product (2014)

- Shire HGT : Review of the cardiac safety of a digestive product (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2012-2013)

Gonzalez Juanatey Jose Ramon

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Kowa : Speaker fee (2012-2013)

- Boehringer-Ingelheim : Speaker fee, AB (2012-2013)

- Servier : Speaker fee, AB (2012-2013)

- Bayer Healthcare : Speaker fee, AB (2012-2013)

- Roche Pharma : Speaker fee, AB (2012-2013)

- Esteve : Speaker fee, AB (2012-2013)

- Almirall Spain : Speaker fee, AB (2012-2013)

- Merck Sharp & Dohme : Speaker fee, AB (2012-2013)

- Astra Zeneca : Cardiovascular (2014)

- Boehringer-Ingelheim : Cardiovascular (2014)

- Daiichi Sankyo : Cardiovascular (2014)

- Novartis : Cardiovascular (2014)

- Servier : Cardiovascular (2014)

- Menarini : Cardiovascular (2014)

- Merck Sharp & Dohme : Cardiovascular (2014)

- Bayer AG : Cardiovascular (2014)

Gorenek Bulent None declared (2012-2013-2014)

Heyndrickx Guy Robert None declared (2012-2013-2014)

29/07/2014




of 45

Hoeft Andreas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - B.Braun : consultancy fees (2012)

- Edwards Lifesciences : speaker fees (2012-2013-2014)

- BBraun : consultancy fees (2013-2014)

Huber Kurt A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : atorvastatin, edoxaban (2012-2013-2014)

- Medicines Company : bivalirudin; cangrelor (2012-2013-2014)

- BRAHMS GmbH : copeptin assay (2012-2013-2014)

- Boehringer-Ingelheim : dabigatran (2012-2013-2014)

- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab (2012-2013-2014)

- Bayer : rivaroxaban (2012-2013-2014)

- Astra Zeneca : ticagrelor; rosuvastatin (2012-2013-2014)

- Bristol Myers Squibb / Pfizer : Apixaban (2014)

- Daiichi Sankyo : edoxaban (2014)

Iung Bernard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : benfluorex (2012)

- Bayer : rivaroxaban (2012-2013)


- Edwards Lifesciences : heart valve prosthesis (2012-2013-2014)

- Abbott : Mitraclip (2012-2013-2014)

Kjeldsen Keld Per None declared (2012-2013-2014)

Knuuti Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014)

D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012-2013-2014)

29/07/2014




of 45

Knuuti Juhani - Athera : vascular inflammation (2012-2013-2014)

- Orion Pharma : Heart failure drug research (2014)

Kristensen Steen Dalby A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : antitrombotics (2012)

- Boehringer-Ingelheim : antitrombotics (2012)

- Eli Lilly : antitrombotics (2012)

- Pfizer : antitrombotics (2012)

- Bayer Healthcare : antitrombotics (2012)

- Medicines Company : antitrombotics (2012)

- Bristol Myers Squibb : antitrombotics (2012)

- Boehringer-Ingelheim : speaker fee, anti-thrombotics (2013)

- Menarini : speakers fee (2013)

- Astra Zeneca : speakers fee, anti-thrombotics (2013)

- Eli Lilly : speakers fee, anti-thrombotics (2013)

- Pfizer : speakers fee, anti-thrombotics (2013)

- Bayer Healthcare : speakers fee, anti-thrombotics (2013)

- Medicines Company : speakers fee, anti-thrombotics (2013)

- Bristol Myers Squibb : speakers fee, anti-thrombotics (2013)

- Pfizer : anti-thrombotics apixaban (2014)

- Bristol Myers Squibb : anti-thrombotics apixaban (2014)

- Medicines Company : anti-thrombotics cangrelor (2014)

- Biotronik : stents (2014)

29/07/2014




of 45

Kristensen Steen Dalby D - Research funding (departmental or institutional). - Astra Zeneca : ticagrelor (2014)

Longrois Dan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Anesthetic drugs (2012)

- Baxter : anesthetic drugs, esmolol (2012-2013-2014)

- Pfizer : Anticoagulants (2012-2013-2014)

- LFB : Blood-derived hemostatic products (2012-2013-2014)

- Orion Pharma : Levosimendan, dexmedetomidine (2012-2013-2014)

- AbbiVie : Anesthetic drugs (sevoflurane) (2013-2014)

- Eusapharma : Custodiol (cardioplegic solution) (2013-2014)

- Masimo : Monitors of SpO2 and near infrared spectroscopy (2014)

D - Research funding (departmental or institutional). - Baxter : Anesthetic drugs, esmolol (2012)

- Sorin Group : Cardiopulmonary bypass equipment (2012-2013-2014)

- Baxter : Anesthetic drugs, esmolol (150.000 dollars for a single study that is now finished) (2013-2014)

Luscher Thomas Felix A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Mitraclip Research Grant (2012)

- Bayer Health Care International : Events adjudication committee (2013)

- Dacadoo, Zurich : Prevention (2013)

- St. Jude : Primary investigator ENLIGHTMENT trial (2013)

- Oxford University Press, Oxford, UK : Editor European Heart Journal (2014)

- Bayer Healthcare : Member, Events Adjudication Committee ARRIVE (2014)

- Dacadoo Zurich : Prevention (2014)

- St. Jude Medical, Minneapolis, USA : Primary Investigator Enlightment trial (2014)

29/07/2014




of 45

Luscher Thomas Felix B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Any (2012)

C - Receipt of royalties for intellectual property. - Roche Pharma : CETP-Inhibition with Dalcetrapib (2012)

D - Research funding (departmental or institutional). - Roche Diagnostics : Researchgrant Biomarkers in ACS (2012)

- Roche Diagnostics : Research grant Biomarkers in ACS (2013)

E - Research funding (personal). - St. Jude : Fellowship in device research (2012)

- Merck Sharp & Dohme : Research grant lipoproteins in reanl failure (2012)

- Eli Lilly : Reserch contract bleeding with prasurgrel (2012)

- Sorin Group : Reserch grant in device research (2012)

- Biotronik : Educational grant (2012-2013)

- Astra Zeneca : Research grant for Swiss ACS registry (2012-2013)

- Biosensors : Research stipend in interventional cardiology (2012-2013)

- Pfizer, New York and Cambridge, USA : Development of MPO inhibitor (2013)

- St. Jude : Educational grant (2013)

- Novartis : Educational grant in heart failure management (2013)

- Servier : Educational grant in heart failure management (2013)

- Bayer Healthcare, Berlin, D : Educational grant in heart failure management (2013)

- Biosensors, D-A-CH : Effects of biolimus-eluting stent on mortality in patients with cardiogenic shock (2013)

- MARS, Inc., Rockville, MD, USA : Effects of epicathecin on coronary vasomotor (2013)

- Cardiorentis : Molecular mechanisms of ularitide (2013)

- Bayer, Switzerland : Perfusion imaging with MRI (2013)

29/07/2014




of 45

Luscher Thomas Felix - Eli Lilly. Indianapolis, IN, USA : Reserch contract bleeding with prasurgrel (2013)

- Pfizer, New York and Cambridge, USA : Basic research grant (2014)

- Eli Lilly, Indianapolis : Bleeding after ACS cohort (Research grant) (2014)

- Roche Diagnostics, Rotkreut, Switzerland : Diagnostics (2014)

- Biotronik : Educational and research grant (2014)

- Bayer Healthcare, Berlin, D : Educational grant (2014)

- St. Jude Medical, Brussels and Zurich : Educational grant (2014)

- Servier, Paris : Educational grant (2014)

- Novartis, Basel, Switzerland : Educational grant (2014)

- MARS, Rockville, USA : Research grant (2014)

- AstraZeneca, Switzerland : Research Grant (together with Bern, Lausanne and Geneva) (2014)

- Cardiorentis Zug, Switzerland : Research grant on ularitide (2014)

- Bayer Healthcare, Switzelrand : Research grants (2014)

- Biosensors : SHOCK Trial (2014)

Pierard Luc A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Siemens Healthcare : Echo machine (2012)

- GE Healthcare : Echo machine VIVID (2012)

- Bayer Healthcare : Rivaroxaban (2012)

- Astra Zeneca : Rosuvastatine, Ticagrelor (2012)

- Novartis : Aliskirene (2013-2014)

- Astra Zeneca : Rosuvastatin (2013-2014)

- Boehringer-Ingelheim : Dabigatran (2014)

29/07/2014




of 45

Pierard Luc D - Research funding (departmental or institutional). - Astra Zeneca : Rosuvastatine (2013-2014)

Pocock Stuart J None declared (2012-2013-2014)

Price Susanna A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : educational contract (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : MItraclip (2013-2014)

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : antiplatelet therapy (2012-2013)

- Lilly : antiplatelet therapy (2012-2013)

- Astra Zeneca : antipletelet therapy (2012-2013)

D - Research funding (departmental or institutional). - Biosensors : devices (2012-2013-2014)

- Boston Scientific : devices (2012-2013-2014)

- Medtronic : devices (2012-2013-2014)

- Biotronik : devices (2012-2013-2014)

- Abbott Vascular : devices (2012-2013-2014)

Saraste Antti None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Nordic Drugs : Cancer pharmacology (2013-2014)

- GE Healthcare : Cardiac Ultrasound (2013-2014)

- Actelion : Cardiovascular pharmacology (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Cardiac nuclear imaging (2013)

- Novartis : Cardiovascular pharmacology (2013)

- Lilly : Cardiovascular Pharmacology (2013)

29/07/2014




of 45

Saraste Antti - Roche Pharma : Cardiovascular Pharmacology (2013)

- Genzyme : Cardiovascular Pharmacology (2013)

- St Jude Medical : Cardiovascular Structural Interventions (2013)

- Abbott Vascular : Cardiovascular Structural Interventions (2013)

- Abbott : Structural heart disease (2014)

D - Research funding (departmental or institutional). - GE Healthcare : Cardiac nuclear imaging (2013)

- Lantheus Inc : Cardiac nuclear imaging (2013)

- St Jude Medical : Ischemic heart disease (2013-2014)

- Servier : Cardiovascular Pharmacology (2014)

- Intarcia : Diabetes (2014)

- GE Healthcare : Nuclear imaging (2014)

- Lantheus Inc : Nuclear imaging (2014)

Sirnes Per Anton B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

- Merck Sharp & Dohme : Investigartor fee HPS2-THRIVE STUDY (2012)

- Boehringer-Ingelheim : Investigator Fee Relyable study (2012)

- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)

- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)

- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)

- NORMA onbehalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)

- Amgen : Speeker fee (2013)

- Pfizer : speeker fee (2013)

29/07/2014




of 45

Sirnes Per Anton - Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)

- Novartis : Investigatoprs fee CANTOS study (2013-2014)

Sousa Uva Miguel None declared (2012-2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet therapy (2014)

Voudris Vasilis A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Cardiovascular (2012)

- Medtronic : Interventional Cardiology (2013-2014)

29/07/2014




of 45

Agathangelou Petros None declared (2012-2013-2014)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Orion : Inotropi (2012)

- Pfizer : Lipids (2012-2013)

- Sanofi Aventis : Lipids (2012-2013)

- Siemens Healthcare : Markers (2012-2013)

- Astra Zeneca : Platelet inhibition (2012-2013-2014)

- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

- Orion : Heart failure (2013)

Andersen Karl A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : investigator, hypertension, heart failure (2012-2013)

- Novartis : investigator, hypertension, heart failure, cor art disease (2014)

Archbold Andrew None declared (2012-2013-2014)

Benlamin Hisham None declared (2012-2013-2014)

Bertomeu Martinez Vicente A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Anticoagulation (2012-2013-2014)

- Takeda Pharmaceuticals : Diabetes (2012-2013-2014)

- Novartis : Heart Failure (2012-2013-2014)

Ceconi Claudio None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Pharmaceutical (2012)

Christersson Christina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - CSL Behring : Bleeding coagulation speakers fees (2012-2013-2014)

- Bristol Myers Squibb : new oral anticoagulant speakers fees, ARISTOTLE Investigator (2012-2013-2014)

29/07/2014

Guidelines on Non-Cardiac Surgery 2014 (TF32) - Document Reviewers



of 45

Christersson Christina - Boehringer-Ingelheim : REDEEM, REALIGN Investigator (2012-2013-2014)

Claeys Marc A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medicines Company : bivalirudine (2012-2013-2014)

- Eli Lilly : prasugrel, abciximab (2012-2013-2014)

- Abbott Vascular : stents- mitraclip (2012-2013-2014)

- Astra Zeneca : ticagrelor (2012-2013-2014)

D - Research funding (departmental or institutional). - Medtronic : coronary stent and corevalve (2012)

Coca Antonio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskiren; Valsartan, combos (2012)

- Takeda Pharmaceuticals : Azilsartan (2012)

- Chiesi Pharma : Manidipine, Delapril (2012)

- Menarini : Nevibolol; Olmesartan, combos (2012)

- Esteve : Valsartan, Aliskiren, combos (2012)

- Ferrer Internacional : Torasemide; CardioIncode microchips (2012-2013)

- Recordati International : Azilsartan; Lercanidipine; combos (2012-2013-2014)

- Novartis : Aliskiren; Valsartan-Amlodipine; Serelaxin (2013)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2013-2014)

- Daiichi Sankyo : Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2013-2014)

- Esteve : Valsartan-Amlodipine (2013-2014)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2014)

- Novartis : Valsartan-Amlodipine; Serelaxin (2014)

Coman Ioan Mircea A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly : antiplatlet (2012)

29/07/2014




of 45

Coman Ioan Mircea - Amgen Inc : eritropoetin analogues (2012)

- Lung Rx : PHT (2012-2013)

- Daiichi Sankyo : anticoagulants (2012-2013-2014)

- Fournier Laboratories : dyslipidemia (2012-2013-2014)

- Novartis : HF (2012-2013-2014)

- Sanofi Aventis : dyslipidemia (2013-2014)

- Amgen Inc : dyslipidemia (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly : antiplatlet (2012)

- Amgen Inc : eritropoetin analogues (2012)

- Lung Rx : PHT (2012-2013)

- Daiichi Sankyo : anticoagulants (2012-2013-2014)

- Fournier Laboratories : dyslipidemia (2012-2013-2014)

- Novartis : HF (2012-2013-2014)

- Sanofi Aventis : dyslipidemia (2013-2014)

- Amgen Inc : dyslipidemia (2013-2014)

Corra Ugo None declared (2012-2013-2014)

Coutinho Joao Manuel Pereira

None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Advisory Board MSD : Lipids (2012)

De Caterina Raffaele A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : aliskiren (2012-2013-2014)

- BMS/Pfizer : apixaban (2012-2013-2014)

- Duke Clinical Research Institute : apixaban - APPRAISE-2 National Coordinator (2012-2013-2014)

29/07/2014




of 45

De Caterina Raffaele - Boehringer-Ingelheim : dabigatran (2012-2013-2014)

- Roche : dalcetrapib (2012-2013-2014)

- Elsevier : Editor-in-Chief, Vascular Pharmacology (2012-2013-2014)

- Daiichi Sankyo : edoxaban (2012-2013-2014)

- Bayer Schering Pharma : rivaroxaban (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskiren trials (2012-2013-2014)

- Roche : dalcetrapib trials (2012-2013-2014)

- Daiichi Sankyo : edoxaban - ENGAGE-AF trial (2012-2013-2014)

- Boehringer-Ingelheim : RELY-ABLE trial (2012-2013-2014)

Deljanin Ilic Marina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Berlin Chemie AG : Speaker fee for lecture about zofenopril (2012)

- Merck Sharp & Dohme : Speaker fee for lecture about treatment of hypertension, focused on beta blocker (bisoprolol) and amlodipin (2013)

- Berlin Chemie AG : Speaker fee for lecture about Smile Studies (2014)

Di Mario Carlo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Biomatrix stent (2012-2013-2014)

- Abbott Vascular : Xience stent (2012-2013-2014)

- Boston Scientific : CTO recanalisation (2013-2014)

- Asahi INTECC : CTO recanalisation (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Ikaria : Cardiac remodelling (2012)

- Daiichi Sankyo, Eli-Lilly : Prasugrel (2012-2013-2014)

- Medtronic : Resolute (2012-2013-2014)

C - Receipt of royalties for intellectual property. - St Jude Medical : Optical coherence tomography (2012-2013)

29/07/2014




of 45

Di Mario Carlo D - Research funding (departmental or institutional). - Medicines Company : Bivalirudine (2012-2013-2014)

- Abbott Vascular : EXCEL Study (2013-2014)

- St Jude Medical : Ilumien OCT (2013-2014)

- Medtronic : RESOLUTE 3 Study (2013-2014)

Dubrava Juraj A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : ivabradine (2012-2013-2014)

- Boehringer-Ingelheim : dabigatran (2014)

- Bayer AG : rivaroxaban (2014)

- Astra Zeneca : ticagrelor (2014)

Duplyakov Dmitry A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Twinsta (2012-2013)

- Takeda Pharmaceuticals : Bisoprolol (2012-2013-2014)

- Pfizer : Eplerenon (2012-2013-2014)

- Merck Sharp & Dohme : ezetimibe (2012-2013-2014)


- Actavis : Lopirel (2012-2013-2014)

- Abbott : Omacor (2012-2013-2014)

- Bayer Healthcare : Rivaroxaban (2012-2013-2014)

- Astra Zeneca : Ticagrelor (2012-2013-2014)

Edvardsen Thor None declared (2012-2013-2014)

Fagard Robert None declared (2012-2013-2014)

Gabulova Rahima None declared (2012-2013-2014)

Germano Giuseppe None declared (2012-2013-2014)

29/07/2014




of 45

Goudev Assen None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2013-2014)

Guarracino Fabio None declared (2014)

C - Receipt of royalties for intellectual property. - Elsevier : Books (2012-2013)

Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)

- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)

D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

Joergensen Torben None declared (2012-2013-2014)

Juni Peter None declared (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - see below : see below (2013)

29/07/2014




of 45

Juni Peter D - Research funding (departmental or institutional). - see below : CTU Bern is involved in design, conduct or analysis of clinical studies funded by Abbott Vascular, Ablynx, Amgen, AstraZeneca, Biosensors, Biotronik, Boehrhinger Ingelheim, Eisai, Eli Lilly, Exelixis, Geron, Gilead Sciences, Nestlé, Novartis, Novo Nordisc, Padma, Roche, Schering-Plough, St. Jude Medical, and Swiss Cardio Technologies. (2014)

Kelm Malte A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Antithrombotics (2012-2013-2014)

D - Research funding (departmental or institutional). - Philips : Imaging (2012-2013-2014)

- Edwards Lifesciences : Transcatheter Aortic Valve Implantation (2012-2013-2014)

- Medtronic : Transcatheter Aortic Valve Implantation (2012-2013-2014)

Kiss Robert Gabor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : apixaban (2012-2013-2014)


- Bayer Healthcare : rivaroxaban (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - TIMI group : steering committee member (2012-2013-2014)

Kurlianskaya Alena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Takeda Pharmaceuticals : Heart Failure (speaker) (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : QUALIFY (investigator) (2012-2013-2014)

Latkovskis Gustavs A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Zentiva : Antiplatelets (2012)

- Nycomed : Cardiovascular risk (2012)

- Solvay : Dyslipidemia (2012)

- Merck Sharp & Dohme : Dyslipidemias (2012)

- Krka Pharma : Dyslipidemias (2012)

- Sanofi Aventis : Antiplatelets (2012-2013)

- Takeda Pharmaceuticals : Cardiovascular risk (2012-2013)

29/07/2014




of 45

Latkovskis Gustavs - Novo-Nordisk : Diabetes (2012-2013)

- Servier : Hypertension (2012-2013)

- Abbott Laboratories : lipid-lowering drugs (2012-2013)

- GlaxoSmithKline : LPH (2012-2013)

- Bayer : Anticoagulants (2012-2013-2014)

- Boehringer-Ingelheim : Anticoagulants (2012-2013-2014)

- Berlin Chemie AG : Antihypertensive agents (2012-2013-2014)

- Merck Serono : Beta blockers (2012-2013-2014)

- Pfizer : Dyslipidemias, anticoagulants (2012-2013-2014)

- University of Latvia : Education (2012-2013-2014)

- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2012-2013-2014)

- Siemens Healthcare : hs-troponin I (2012-2013-2014)

- Astra Zeneca : lipid-lowering drugs, anti platelets (2012-2013-2014)

- Servier : Hypertension, heart rate (2014)

D - Research funding (departmental or institutional). - Pfizer : Anticoagulation (2012)

- Latvian Council of Science : Genetics of CVD (2012-2013)

E - Research funding (personal). - Merck Sharp & Dohme : Dyslipidemia (2012)

- Bayer : Anticoagulation (2012-2013)

- Merck Serono : bisoprolol and amlodipine combination (2012-2013-2014)

- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2014)

Lindgren Kai None declared (2012-2013-2014)

29/07/2014




of 45

Mahdhaoui Abdallah None declared (2012-2013-2014)

Marinskis Germanas None declared (2012-2013-2014)

Marques-Vidal Pedro A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Ethical Committe of the VD Canton, Switzerland : As statistical expert (2012)

- ZonMw (Netherlands Organisation for Health Research and Development) : As reviewer for grant proposals (2012-2013)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lausanne antidoping laboratory : Antidoping tests - as consultant in statistics (2014)

D - Research funding (departmental or institutional). - Swiss Federal Office of Public Health : To conduct the national nutrition survey (2012)

- Swiss National Funding Agency : Scholarship for a PhD student in public health nutrition (2013)

- Leenaards foundation (nonprofit organization) : Clinical investigation grant on new cardiovascular risk factors (2014)

Metzler Bernhard None declared (2012-2013-2014)

Mirrakhimov Erkin None declared (2012-2013-2014)

Mueller Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Alere : Diagnostics (2012)

- Novartis : Acute Heart FAilure (2012-2013-2014)

- BRAHMS GmbH : Diagnostics (2012-2013-2014)

- Roche Diagnostics : Diagnostics (2012-2013-2014)

- Cardiorentis : Acute Heart Failure (2013-2014)

- Abbott Laboratories : Diagnostics (2013-2014)

- BG medicine : Diagnostics (2013-2014)

- BioMérieux S.A : Diagnostics (2013-2014)

- Siemens : Diagnostics (2013-2014)

- Astra Zeneca : Diagnostics (2014)

29/07/2014




of 45

Mueller Christian - Lilly : Diagnostics (2014)

D - Research funding (departmental or institutional). - Medicines Company : Acuet Heart FAilure (2012)

- Swiss Heart Foundation : Diagnostics (2012)

- Beckman Coulter : Diagnostics (2012)

- Nanosphere : Diagnostics (2012)

- BRAHMS GmbH : Diagnostics (2012-2013-2014)

- Abbott Laboratories : Diagnostics (2012-2013-2014)

- Roche Diagnostics : Diagnostics (2012-2013-2014)

- Siemens : Diagnostics (2013-2014)

Oto Oztekin None declared (2012-2013-2014)

Pagava Zurab A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Berlin Chemie AG : Spieker fees (2012-2013)

- Servier : Spieker fees (2012-2013)

- Berlin Chemie AG (Georgia) : Spieker fees (2014)

- Servier (Georgia) : Spieker fees (2014)

- AstraZeneca (Georgia) : Spieker fees (2014)

Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : ivabradin, trimetazidin (2012)

- Servier : trimetazidin, rivaroxaban, ticagrelor (2013)

- Boehringer-Ingelheim : dabigatran (2014)

- Astra Zeneca : ticagrelor (2014)

- Servier : trimetazidin, ivabradin (2014)

29/07/2014




of 45

Parkhomenko Alexander B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : rivaroxabane (2012-2013-2014)

C - Receipt of royalties for intellectual property. - BHFZ : corvitine (2012-2013-2014)

Pibarot Philippe B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Juude Medical : Proesthetic Heart Valves (2014)

- Edwards Lifesciences : Transcatheter Heart Valves (2014)

D - Research funding (departmental or institutional). - Edwards Lifesciences : Transcatheter Heart Valves (2012-2013-2014)

- V-Wave Ltd : Heart Failure Therapy (2013-2014)

Piepoli Massimo Francesco None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : heart failure (2012)

- Cothera : heart failure (2012)

- Coridea : heart failure (2012)

- Boehringer-Ingelheim : anticoagulant (2012-2013-2014)

- Bristol Myers Squibb : anticoagulant (2012-2013-2014)

- Respicardia : anticoagulant (2012-2013-2014)


- Novartis : heart failure (2012-2013-2014)

- Johnson & Johnson : heart failure (2012-2013-2014)

- Bayer Healthcare : heart failure (2012-2013-2014)

- Vifor Pharma ltd : heart failure (2012-2013-2014)

- Pfizer : heart failure, anticoagulant (2012-2013-2014)

29/07/2014




of 45

Ponikowski Piotr - Servier : heart failure, coronary artery disease (2012-2013-2014)

- Bayer : anticoagulant (2013-2014)

- ROSCHE : diabetes (2013-2014)

- Cardiorentis : heart failure (2013-2014)

- CIBIEM : heart failure (2013-2014)

- Amgen : heart failure, lipids (2013-2014)

D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012-2013-2014)

Romeo Francesco None declared (2012-2013-2014)

Saade Georges A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Consultancy (2012-2013)

- Novartis : Honoraria (2012-2013)

- Sanofi Aventis : Speaker fees (2012-2013-2014)

- Merck Serono : Speaker Fee (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Investigator (2012-2013)

- Boehringer-Ingelheim : Committee Member (2014)

E - Research funding (personal). - Boehringer-Ingelheim : A. Fibrillation (2012-2013)

- Pfizer : Research (2014)

Sammut Mark Adrian None declared (2012-2013-2014)

Sellevold Olav F Muenter None declared (2012-2013-2014)

Skalicka Hana None declared (2012-2013-2014)

Stepinska Janina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : anticoagulation/apixaban (2012-2013)

29/07/2014




of 45

Stepinska Janina - Eli Lilly : Antiplatelet/prasugrel (2012-2013)

- Astra Zeneca : antiplatelet/ticagrelor (2012-2013)

- Polpharma : heart faiilure/ beta blockers, ACE-inhibitors (2012-2013)

- Bristol Myers Squibb : anticoagulation/apixaban (2012-2013-2014)

- Boehringer-Ingelheim : anticoagulation/dabigatran (2012-2013-2014)

- Bayer Healthcare : anticoagulation/rivaroxaban (2012-2013-2014)

- Servier : heart failure/ivabradine (2012-2013-2014)

- Abbott : ACS/stents (2013)

- Polpharma : heart failure/beta blockers, ACE inhibitors (2014)

- Novartis : heart failure/relaxin (2014)

- Krka Pharma : hypertension/hyperlipidemia (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Travena INC : Acute heart failure/ TRV 120027 (2012)

- Cothera : acute heart failure/relaxin (2012)

- Bayer : atrial fibrillation, registry (2012-2013)

- Astra Zeneca : ACS, registry (2012-2013-2014)

- Novartis : avute heart failure/relaxin (2012-2013-2014)

- Servier : stable angina, registry (2012-2013-2014)

- Bayer : atrial fibrillation, registry, anticoagulation in heart failure (2014)

- Zoll Medical : hypothermia (2014)

Terzic Ibrahim None declared (2012-2013-2014)

Thomopoulos Costas None declared (2012-2013-2014)

29/07/2014




of 45

Triposkiadis Filippos Koustantino

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2012)

- Servier : Ivabradine (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Serelaxin (2012-2013-2014)

- Menarini : Ranolazine, nebovilol (2013)

- Astra Zeneca : Ticagrelor (2013-2014)

D - Research funding (departmental or institutional). - Menarini : Ranolazine (2012-2013)

Ural Dilek None declared (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Dabigatran (2012)

- Boehringer-Ingelheim : Dabigatran (2013)

- Bayer AG : rivaroxabane (2013)

Vanzetto Gerald A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Acute coronary syndroms - Ivabradine (2012-2013)

- Medicines Company : Acute coronary syndroms - Bivalirudine (2012-2013-2014)

- Daiichi Sankyo : Acute coronary syndroms - Prasugrel (2012-2013-2014)

- Lilly : Acute coronary syndroms - Prasugrel (2012-2013-2014)

- Astra Zeneca : Acute coronary syndroms - Ticagrelor (2012-2013-2014)

D - Research funding (departmental or institutional). - Medicines Company : Acute coronary syndrom trials (2012-2013)

- Boston Scientific : Interventional Cardiology (2012-2013-2014)

- Abbott Vascular : Interventional Cardiology (2012-2013-2014)

- Biosense : Interventional Cardiology (2012-2013-2014)

- Actelion : Pulmonary hypertension (2014)

29/07/2014




of 45

Vanzetto Gerald - Biosensors : Rhythmology (2014)

- Medtronic : Rhythmology (2014)

Vavlukis Marija None declared (2012-2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Alkaloid AD Skopje : ACE inhibitor (2014)

Vered Zvi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Speakers Training Meeting regarding Apixaban (2012)

- Pfizer : Speaker training - Budapest, 2013 (2013)

D - Research funding (departmental or institutional). - F. Hoffman La Roche Ltd : Dalcetrapib (2012)

- Gilead : Ranolazin (2012)

- Astellas : Vernakalant (2012)

- Bayer Healthcare : BAY 94-8862 (2012-2013)

- Sanofi Aventis : Otamixaban (2012-2013-2014)

- Sanofi Aventis : SAR236553/REGN727 (2012-2013-2014)

- Bayer AG : BAY 94-8862 (2014)

Vestergaard Lone None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Speaker fee on ECG interpretation (2013-2014)

- Boehringer-Ingelheim : Speaker fee on preoperative evaluation (2013-2014)

Viigimaa Margus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Coagulation (2012)

- Merck Sharp & Dohme : Dyslipidemia (2012-2013)

- GlaxoSmithKline : Coagulation (2012-2013-2014)

- Boehringer-Ingelheim : Hypertension (2012-2013-2014)

29/07/2014




of 45

Viigimaa Margus - Menarini : Hypertension (2012-2013-2014)

- Gedeon Richter : Hypertension (2013-2014)

Wijns William B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Tryton : device (2012)

- Astra Zeneca : pharma (2012)

- Biosensors : device (2012-2013-2014)

- Boston Scientific : device (2012-2013-2014)

- Edwards Lifesciences : device (2012-2013-2014)

- Medtronic : device (2012-2013-2014)

- St Jude Medical : device (2012-2013-2014)

- Biotronik : device (2012-2013-2014)

- Terumo Inc : device (2012-2013-2014)

- Abbott Vascular : device (2012-2013-2014)

- Cordis : device (2012-2013-2014)

- Orbus Nech : device (2012-2013-2014)

- MICELL : device (2012-2013-2014)

- Vessix : device (2012-2013-2014)

- GlaxoSmithKline : drug (2012-2013-2014)

D - Research funding (departmental or institutional). - Cardio3 Biosciences : cell therapy (2012-2013-2014)




29/07/2014




of 45

Wijns William - Biotronik : device (2012-2013-2014)

- Abbott Laboratories : device (2012-2013-2014)

- MICELL : device (2012-2013-2014)

- Therabel : drug (2012-2013-2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stent (2012)

- Boston Scientific : Stent (2012)

- Cordis : Stent (2012)

- Edwards Lifesciences : TAVI (2012)

- Astra Zeneca : Antiplatelet drug (2012-2013)

- Eli Lilly : Antiplatelet drug (2012-2013)

- Abbott : Stent (2012-2013)

- Medtronic : Stent (2012-2013)

- Biotronik : Stent (2012-2013)

D - Research funding (departmental or institutional). - Abbott : Stent (2012)

- Biosensors : Stent (2012)

- Medtronic : Stent (2012)


- St Jude Medical : OCT (2012-2013-2014)

- Biotronik : Stent (2012-2013-2014)

Wouters Patrick B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Covidien : NIRS and neuro monitoring (2013-2014)

29/07/2014




of 45

Wouters Patrick - AbbVie : volatile anesthetics (2013-2014)

D - Research funding (departmental or institutional). - Fresenius Nutrition : Volume Expanders, Anesthetic Drugs (2012-2013-2014)

29/07/2014




of 45

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Siemens Healthcare : CT (2012-2013)

- Servier : Imaging (2012-2013)

- Guerbet : Imaging (2012-2013)

- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

D - Research funding (departmental or institutional). - Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2014)

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan for PAH treatment in congenital heart disease (2012)

- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)

- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)

- Direct Flow Medical : transcatheter valve implantation (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan for PAH treatment in congenital heart disease (2012-2013-2014)

- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)

- Direct Flow Medical : transcatheter valve implantation (2013-2014)

29/07/2014

Committee for Practice Guidelines 2012-2014



of 45

Bax Jeroen D - Research funding (departmental or institutional). - Servier : Farma (2012-2013-2014)

- Edwards Lifesciences : Heart Valves (2012-2013-2014)

- GE Healthcare : Imaging (2012-2013-2014)

- Lantheus Inc : Imaging (2012-2013-2014)

- Boston Scientific : Pacing (2012-2013-2014)

- Medtronic : Pacing (2012-2013-2014)

- St Jude Medical : Pacing (2012-2013-2014)

- Biotronik : Pacing (2012-2013-2014)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Heart Failure and elinogrel (2012)

- Bayer Healthcare : Aspirin, rivaroxaban (2012-2013-2014)

- Roche Pharma : Dalcetrapib (2012-2013-2014)

- Daiichi Sankyo : Prasugrel (2012-2013-2014)

- Eli Lilly : Prasugrel (2012-2013-2014)


- BMS/Pfizer : Apixaban (2013)

- Novartis : Relaxin (2013)

- Sanofi Aventis : Clopidogrel (2013-2014)

- Pfizer : Apixaban (2014)

- Bristol Myers Squibb : Apixaban (2014)

- Menarini : Ranolazine (2014)

- Novartis : Serelaxin (2014)

29/07/2014




of 45

Bueno Hector E - Research funding (personal). - Astra Zeneca : Ticagrelor (2012-2013-2014)

Deaton M Christi None declared (2013-2014)

D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012)

- Menarini : Trandolapril (2012)

- Menarini : Hypertension (2013-2014)

C - Receipt of royalties for intellectual property. - Astra Zeneca : Ticagrelor (2012)

Fagard Robert None declared (2012-2013-2014)

Ferrari Roberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoaguland and diabetes. Dagabitran (2012)

- Medical Trials Analysis : Consultant in Clinical Trials (2012)

- Servier : Myocardial ischamia and heart failure. Perindopril, ivabradine, alodipine, trimetazidine (2012)

- Novartis : Acute heart failure. Saralaxine (2013-2014)

- Boehringer-Ingelheim : Anticoagulants and diabetes. Dagabitran (2013-2014)

- Medical Trials Analysis : Consultant in clinical trials - expertise (2013-2014)

- Merk Serono : Coronary artery disease, heart failure, beta blockers (2013-2014)

- Servier : Myocardial ischemia and heart failure. Perindopril, Ivabradine, Amlodipine, Trimetazedine (2013-2014)

D - Research funding (departmental or institutional). - Fondazione Salvatore Maugeri : General (2012)

- Schering-Plough : Anti-platelet agent TRACER (2012-2013-2014)

29/07/2014




of 45

Ferrari Roberto - Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012-2013-2014)

Hasdai David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Pradaxa (2012-2013-2014)

- Bayer : Rivaroxiban (2012-2013-2014)


Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)

- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)

D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular (2012-2013-2014)

- Daiichi Sankyo : cardiovascular (2012-2013-2014)

- Medtronic : cardiovascular (2012-2013-2014)

- Pfizer : cardiovascular (2012-2013-2014)

- St Jude Medical : cardiovascular (2012-2013-2014)

29/07/2014




of 45

Kirchhof Paulus - Sanofi Aventis : cardiovascular (2012-2013-2014)

- Meda pharma : cardiovascular (2012-2013-2014)

- Bristol Myers Squibb : cardiovascular (2012-2013-2014)

- Merck Sharp & Dohme : cardiovascular (2012-2013-2014)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014)

- Johnson & Johnson : cardiovascular (2014)

- Bayer Healthcare : cardivoascular (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Portola Pharmaceuticals : cardiovascular (2012)

- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)

- Bayer Healthcare : cardiovascular (2012-2013-2014)

- BMS / Pfizer alliance : cardiovascular (2012-2013-2014)

- Gilead : cardiovascular (2013)

- Daiichi Sankyo : cardiovascular (2014)

D - Research funding (departmental or institutional). - St Jude Medical : cardiovascular (2012-2013)

- Sanofi Aventis : cardiovascular (2012-2013)

- Meda pharma : cardiovascular (2012-2013-2014)

- British Heart Foundation : cardiovascular (2014)

- European Union (FP7) : cardiovascular (2014)

- Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014)

- St Jude Medical : cardiovascular (IIT grant to AFNET) (2014)

- Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014)

29/07/2014




of 45

Kirchhof Paulus - BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014)

- Fondation Leducq : cardiovascular (starting in October 2014) (2014)

- German Ministry of Education and Research (BMBF) : cardivoascular (to AFNET) (2014)

Knuuti Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014)

D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012-2013-2014)

- Athera : vascular inflammation (2012-2013-2014)

- Orion Pharma : Heart failure drug research (2014)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Regado Biosciences : Antithrombotic agents (2012)

- Astra Zeneca : Antiplatelet agents (2012-2013-2014)

- B.Braun : Surgical instruments (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012)

D - Research funding (departmental or institutional). - St Jude Medical : Cardiac valves (2012-2013)

- Boston Scientific : Coronary stents (2012-2013)

- Siemens Healthcare : Medical imaging (2012-2013)

- Johnson & Johnson : Thoracoscopic devices (2012-2013)

- Edwards Lifesciences : Cardiac valves (2012-2013-2014)

- Medtronic : Cardiac valves (2012-2013-2014)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Heart Failure (2012)

- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

29/07/2014




of 45

Lancellotti Patrizio - Menarini : nebivolol (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Brilique (2012)

- Servier : Coversyl (2012)

- Abbott Vascular : MitraClip (2012)

- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

D - Research funding (departmental or institutional). - Actelion : Pulmonary Hypertension (2013)

Linhart Ales A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Arterial hypertension (2012-2013-2014)

- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014)

- GlaxoSmithKline : Atherosclerosis (2012-2013-2014)

- Merck Sharp & Dohme : Dyslipidemia (2012-2013-2014)

- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014)

- Shire HGT : Fabry disease (2012-2013-2014)

- Genzyme : Fabry disease (2012-2013-2014)

- Actelion : Pulmonary hypertension (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire HGT : Fabry disease (2012)

D - Research funding (departmental or institutional). - Shire HGT : Fabry disease (2014)

Nihoyannopoulos Petros None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Consultant for Imaging studies (2013-2014)

29/07/2014




of 45

Piepoli Massimo Francesco None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : heart failure (2012)

- Cothera : heart failure (2012)

- Coridea : heart failure (2012)

- Boehringer-Ingelheim : anticoagulant (2012-2013-2014)

- Bristol Myers Squibb : anticoagulant (2012-2013-2014)

- Respicardia : anticoagulant (2012-2013-2014)


- Novartis : heart failure (2012-2013-2014)

- Johnson & Johnson : heart failure (2012-2013-2014)

- Bayer Healthcare : heart failure (2012-2013-2014)

- Vifor Pharma ltd : heart failure (2012-2013-2014)

- Pfizer : heart failure, anticoagulant (2012-2013-2014)

- Servier : heart failure, coronary artery disease (2012-2013-2014)

- Bayer : anticoagulant (2013-2014)

- ROSCHE : diabetes (2013-2014)

- Cardiorentis : heart failure (2013-2014)

- CIBIEM : heart failure (2013-2014)

- Amgen : heart failure, lipids (2013-2014)

D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012-2013-2014)

29/07/2014




of 45

Sirnes Per Anton B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

- Merck Sharp & Dohme : Investigartor fee HPS2-THRIVE STUDY (2012)

- Boehringer-Ingelheim : Investigator Fee Relyable study (2012)

- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)

- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)

- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)

- NORMA onbehalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)

- Amgen : Speeker fee (2013)

- Pfizer : speeker fee (2013)

- Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)

- Novartis : Investigatoprs fee CANTOS study (2013-2014)

Tamargo Juan Luis A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)

- Menarini : Ranolazina (2013)

- Menarini : Ranolazine (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014)

D - Research funding (departmental or institutional). - Astra Zeneca : Unrestricted Grant (2013)

E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)

- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)

Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012)

- Amgen : Darbopoietin (2012)

29/07/2014




of 45

Tendera Michal - Servier : Ivabradine, Phase II investigational products (2012)

- Amgen : Darbopoietine (2013)

- Bayer : Aspirin, Acarbose (2013-2014)

- Servier : Ivabradine (2013-2014)

- Janssen Cilag : Rivaroxaban (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)

- Servier : Ivabradine (2014)

- Janssen-Cilag : Rivaroxaban (2014)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Cardiomems : implanted pulmonary artery pressure sensor (2012)

- United Therapeutics : Pulmonary arterial hypertension (2012)

- Lilly : pulmonary arterial hypertension - tadalafil (2012)

- AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012)

- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)

- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2012-2013)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2012-2013-2014)

- Bristol Myers Squibb : Pulmonary arterial hypertension (2013)

- Lilly : pulmonary arterial hypertension - ambrisentan (2013)

- Novartis : pulmonary hypertension (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Thromboembolic disease (2012)

- Bayer Healthcare : Pulmonary hypertension (2012-2013-2014)

29/07/2014




of 45

Wijns William B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Tryton : device (2012)

- Astra Zeneca : pharma (2012)

- Biosensors : device (2012-2013-2014)


- Edwards Lifesciences : device (2012-2013-2014)




- Terumo Inc : device (2012-2013-2014)

- Abbott Vascular : device (2012-2013-2014)

- Cordis : device (2012-2013-2014)

- Orbus Nech : device (2012-2013-2014)

- MICELL : device (2012-2013-2014)

- Vessix : device (2012-2013-2014)

- GlaxoSmithKline : drug (2012-2013-2014)

D - Research funding (departmental or institutional). - Cardio3 Biosciences : cell therapy (2012-2013-2014)





- Abbott Laboratories : device (2012-2013-2014)

29/07/2014




of 45

Wijns William - MICELL : device (2012-2013-2014)

- Therabel : drug (2012-2013-2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stent (2012)

- Boston Scientific : Stent (2012)


- Edwards Lifesciences : TAVI (2012)

- Astra Zeneca : Antiplatelet drug (2012-2013)

- Eli Lilly : Antiplatelet drug (2012-2013)

- Abbott : Stent (2012-2013)

- Medtronic : Stent (2012-2013)

- Biotronik : Stent (2012-2013)

D - Research funding (departmental or institutional). - Abbott : Stent (2012)

- Biosensors : Stent (2012)

- Medtronic : Stent (2012)


- St Jude Medical : OCT (2012-2013-2014)

- Biotronik : Stent (2012-2013-2014)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Help in Design Echocardiographic protocol (2012)

- Merck Sharp & Dohme : Lecture (2012)

- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

29/07/2014




of 45

Zamorano Gomez Jose Luis

- Philips : 3D echo (2014)

- MSD : CV risk factors (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - European Research Foundation FP7 : CV Imaging (2012)

- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014)

C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2012-2013)

D - Research funding (departmental or institutional). - Astra Zeneca : Clinical trial (2014)

- Ikaria : Clinical trial (2014)

29/07/2014




of 45

guidelines on non-cardiac surgery 2014 (tf32) - tf members

Documents